1. Evaluating Next-Generation BTK Inhibitors

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal

4. BTK Overview

5. First-Generation BTK Inhibitor Ibrutinib

6. Second-Generation BTK Inhibitor Acalabrutinib

7. Acalabrutinib and Ibrutinib Dosing

8. Approved Indications Ibrutinib

9. Ibrutinib in Relapsed CLL Phase 1 Data

10. Efficacy of Ibrutinib in Other Disease States

11. Ibrutinib vs Ofatumumab in Previously Treated CLL

12. Ibrutinib AEs

13. Challenges With Ibrutinib Use

14. Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib

15. Management of Atrial Fibrillation

16. Managing Infections

17. Mechanisms of Resistance

18. Acalabrutinib Pharmacodynamics

19. Acalabrutinib in Relapsed CLL Results

20. Acalabrutinib in Relapsed CLL AEs

21. Acalabrutinib in Relapsed/Refractory MCL

22. Acalabrutinib in Relapsed/Refractory MCL AEs

23. Management of Acalabrutinib AEs

24. Acalabrutinib or Ibrutinib?

25. Guideline Recommendations for Ibrutinib and Acalabrutinib

26. Second-Generation BTK Inhibitor Pipeline and Other Novel Combinations

27. Other Novel Combination Trials

28. Genomic-Driven Ibrutinib Treatment in MCL

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)